Zymeworks Inc. (ZYME)
- Previous Close
8.71 - Open
8.76 - Bid 8.52 x 100
- Ask 8.57 x 200
- Day's Range
8.54 - 8.92 - 52 Week Range
6.01 - 13.14 - Volume
327,500 - Avg. Volume
577,241 - Market Cap (intraday)
604.064M - Beta (5Y Monthly) 1.11
- PE Ratio (TTM)
-- - EPS (TTM)
-1.72 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
14.63
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
www.zymeworks.comRecent News: ZYME
Performance Overview: ZYME
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ZYME
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ZYME
Valuation Measures
Market Cap
614.65M
Enterprise Value
267.04M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.89
Price/Book (mrq)
1.32
Enterprise Value/Revenue
3.51
Enterprise Value/EBITDA
-2.21
Financial Highlights
Profitability and Income Statement
Profit Margin
-156.12%
Return on Assets (ttm)
-13.97%
Return on Equity (ttm)
-24.78%
Revenue (ttm)
76.01M
Net Income Avi to Common (ttm)
-118.67M
Diluted EPS (ttm)
-1.72
Balance Sheet and Cash Flow
Total Cash (mrq)
374.33M
Total Debt/Equity (mrq)
5.76%
Levered Free Cash Flow (ttm)
-91.5M